{"id":210604,"title":"Summary: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded use of RSVPreF3 for individuals 50-59 years of age and use of the new mRNA-1345 vaccine - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T12:15:56.122000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html","snippet":"Summary: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded use of RSVPreF3 for individuals 50-59 years of age and use of the new mRNA-1345 vaccine - Canada.ca Skip to main content Skip to \"About government\" Language selection…","rawSnapshotUrl":"/api/snapshots/raw/210604","browseUrl":"https://replay.healtharchive.ca/job-1/20250418121556/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html#ha_snapshot=210604","mimeType":"text/html","statusCode":200}